Copyright © 2021. Inderes Oyj. All rights reserved.

Cantargia

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
22.9.
2021

Cantargia AB today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation in the US to nadunolimab (CAN04) for the treatment of pancreatic cancer. This provides access to various incentives in the continued clinical development of nadunolimab in pancreatic cancer.

Tiedotteet
16.9.
2021

Cantargia AB today presented novel interim results in non-small cell lung cancer (NSCLC) patients for nadunolimab (CAN04) in combination with gemcitabine/cisplatin at the ESMO Congress. The data read-out was conducted in August 2021 and the efficacy analysis includes 27 patients. In summary, compared to historical controls, the efficacy was higher than for chemotherapy alone, with an overall response rate (ORR) of 53 % in non-squamous NSCLC. In the total population, ORR was 48% and median progression-free survival (PFS) 7.2 months.

Tiedotteet
13.9.
2021

Cantargia AB today announced the publication of an abstract disclosing novel clinical interim data from the CANFOUR study. The abstract was submitted in May 2021 for the upcoming ESMO Congress starting 16 September, 2021. In 15 non-small cell lung cancer (NSCLC) patients evaluated for efficacy, nadunolimab (CAN04) combined with gemcitabine/cisplatin showed an overall response rate (ORR) of 60%, a median duration of response (DOR) of 6.2 months and a median progression-free survival (PFS) of 8.2 months.

Tiedotteet
10.9.
2021

Cantargia AB today announced approval to start the phase I/II clinical study CESTAFOUR by the regulatory authority and ethics committee in France. This study broadens the clinical development for nadunolimab (CAN04) to include biliary tract cancer (BTC), colorectal cancer (CRC) and late-stage non-small lung cancer (NSCLC) and will evaluate CAN04 in combination with standard of care chemotherapy. The study will be conducted at approximately 20 clinical centers in Europe and will include up to a total of 165 patients.

Tiedotteet
10.9.
2021

Cantargia AB today announced that all planned 40 patients with advanced pancreatic cancer (PDAC) have started therapy in the phase IIa extension cohort in the CANFOUR study. Preliminary data from these patients confirm a good safety profile of nadunolimab (CAN04) combined with gemcitabine/nab-paclitaxel. Presentation of safety and efficacy data for the extension cohort is planned for the first half of 2022. Adding this group to the primary group previously analyzed, more than 70 patients with PDAC have now received CAN04 combined with chemotherapy.

Tiedotteet
6.9.
2021

Cantargia AB today announced the clinical development status and next steps of nadunolimab (CAN04) in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC). As therapies differ between subgroups of NSCLC, future development needs to address segments in parallel and Cantargia will prioritize patients most likely to benefit. New interim data to be presented at the ESMO Congress, September 16-21, 2021, indicate the strongest anti-tumor effect in non-squamous NSCLC.

Tiedotteet
1.9.
2021

Cantargia AB (publ) (Cantargia) announced today that Nedjad Losic has been employed as VP Biometrics at Cantargia from 1 September 2021. He will be part of the management team where he will contribute with his extensive experience, from e.g. development of daratumumab at Genmab, of antibodies for cancer treatment.

Tiedotteet
30.8.
2021

Cantargia AB today report new preclinical data on the antibody nadunolimab (CAN04) in combination with the chemotherapy docetaxel. CAN04 increased the anti-tumor effect of docetaxel, but notably, this was not achieved by blocking only one of the pathways targeted by CAN04, using an antibody against IL-1β signaling. Additionally, docetaxel and other chemotherapies induce the release of the other form of IL-1, IL-1α, by tumor cells. These data highlight the potential of CAN04, which blocks both IL-1α and IL-1β, to increase chemotherapy efficacy.

Tiedotteet
26.8.
2021

Cantargia AB today announced that the first patient has received treatment with nadunolimab (CAN04) and FOLFIRINOX in the phase Ib study, CAPAFOUR, investigating treatment of patients with metastatic pancreatic cancer (PDAC). The study will include approximately 30 patients at multiple sites in France and Spain.

Tiedotteet
19.8.
2021

Cantargia AB today announced that the last patient in the initial treatment arm of the phase Ib clinical study CIRIFOUR has started treatment. A total of 15 patients have so far been recruited to this study, which evaluates nadunolimab (CAN04) in combination with Keytruda® (pembrolizumab), and preliminary data indicate a good safety profile. The CIRIFOUR study protocol will now be expanded to include the next combination therapy arm where CAN04 is evaluated with pembrolizumab and platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC).

Cantargia